Adaptive Biotechnologies again increased its 2026 revenue outlook as its minimal residual disease (MRD) business continued to expand. The Seattle-based company now expects 2026 MRD revenue of $268 million–$278 million, up from $260 million–$270 million, after Q2 MRD revenue rose 33% year over year to $66.2 million. Overall Q2 revenue grew 22% to $71.6 million, helped by higher clinical testing volumes, including 36,111 ClonoSEQ tests delivered to clinical customers. Management said blood-based testing accounted for 51% of volume, and community testing represented 36% of total tests. Adaptive also pointed to expanding MRD use in care delivery, noting that serial monitoring tests ordered through OncoEMR reached a 75% fulfillment rate—an indicator of adoption beyond one-time testing for some indications.